🔗 Share this article

Elected officials have issued warnings that the United Kingdom's recent agreements with the US administration are "fundamentally unstable." This follows revelations that a recently announced deal on drug pricing, which commits to zero tariffs in exchange for the NHS facing higher prices, lacks any detailed agreement beyond broad headline terms outlined by government press releases.

Lacking Legal Footing

The deal on drug tariffs, described as a "generational" achievement, is still an "statement of intent" without formal ratification. Critics have noted that the press releases from the UK and US governments describe the deal in sharply different terms. The British version emphasizes securing "duty-free access" as a unique achievement, while the American announcement dwells on the commitment for the NHS to pay 25% more for new medications.

"There is a serious risk that the UK government has promised concessions to increase medicine costs in return for nothing more than a pledge from President Trump," commented David Henig, a trade policy analyst. "We know he has form for not honouring his word."

Wider Concerns Amidst a Suspended Agreement

Concerns have been heightened by Washington's action to pause the £31bn "tech prosperity deal", which was previously called "a huge leap forward" in the bilateral relationship. The US claimed a failure to advance from the UK on lowering trade barriers as the reason for the pause.

Furthermore, concessions secured for British farmers as part of an earlier tariff deal have yet to be formally signed off by the US, despite a fast-approaching January deadline. "It is our belief that the US has not finalized the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Anxiety Behind Closed Doors

In confidential discussions, ministers have voiced worries that the government's deals with Washington are unstable and unpredictable. One minister described the series of agreements as "built on sand," while another framed the situation as the "new normal" in the transatlantic relationship, marked by "increased uncertainty and instability."

Layla Moran, chair of the health select committee, remarked: "The only thing more surprising than the US approach is the UK government's naive belief that his administration is a good faith actor. The NHS is of vital importance."

Official Reassurances and Concrete Outcomes

Officials have attempted to minimize the chances of the US backing out of the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been pushing for the agreement, desiring stability on imports and pricing, making it less abstract than the paused tech deal.

Officials admit that volatility is part and parcel of dealing with the Trump administration. However, they contend that the UK has achieved real benefits for businesses, such as preferential tariff rates compared to other nations. "Our achievement of 25% steel tariffs, which is more favorable than the rate for the rest of the world, is a concrete advantage," one official said.

Yet, issues have emerged in implementing the broader trade deal. Promised quotas on beef exports have not materialized, and the commitment to "reduce steel tariffs to zero" has not been fulfilled, with tariffs fixed at 25%.

Moving forward, the two sides have scheduled to restart talks on the paused tech prosperity deal in January, following what were described as "productive" meetings between UK and US officials in Washington.